Concepedia

Mark Kerstjens

MK

5

Publications

171

Citations

5

H-Index

2016

Active since

Affiliations

Erasmus MC - Sophia Children’s Hospital(Current)

Princess Máxima Center

University of Padua

Mark Kerstjens is an author at Erasmus MC - Sophia Children’s Hospital specializing in tumor biology, immunology, and cancer research.

Top concepts

Publications per year

2016–2021

5

Publications

5

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis

P Garrido Castro, Eddy H.J. Van Roon, Sandra S. Pinhanços et al. · Leukemia · 2017 · 73 citations

, , +10

MEK inhibition is a promising therapeutic strategy for <i>MLL</i>-rearranged infant acute lymphoblastic leukemia patients carrying <i>RAS</i> mutations

Mark Kerstjens, Emma M. C. Driessen, Merel Willekes et al. · Oncotarget · 2016 · 43 citations · Full text

Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL

Michela Bardini, Luca Trentin, Francesca Rizzo et al. · Molecular Cancer Therapeutics · 2018 · 27 citations

High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells

Lindy Vernooij, Laurel T. Bate-Eya, Lindy K. Alles et al. · Molecular Cancer Therapeutics · 2021 · 18 citations · Full text

Decitabine mildly attenuates <i>MLL</i>‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer

Pauline Schneider, Patricia Garrido Castro, Sandra S. Pinhanços et al. · eJHaem · 2020 · 10 citations · Full text

Rows per page

1–5 of 5